| DB ID | MyCo_1168 |
| Title | (1-->3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease |
| Year | 2005 |
| PMID | 16173245 |
| Fungal Diseases involved | Pneumocystis carinii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | carinii |
| Organism | Pneumocystis carinii |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | Fifteen PCP patients were re - cruited, 10 women and 5 men (mean age: 54.4 ± 4.69 years). |
| Cohort No. | 15 |
| Age Group | 54.4 ± 4.69 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | PCP is one of the most serious infections with immunocompromised hosts, such as acquired immunodeficien-cy syndrome (AIDS), malignancies, or- gan transplantation, and CTD. We fo- cused on CTD, which needs steroids and/or immunosuppressants. Several studies have investigated the risk factors and incidence of PCP in patients with CTD. |
| Technique | Assay |
| Analysis Method | BDG G test Kit (Seikagaku Cor- poration, Tokyo Japan) |
| ELISA kits | BDG G test Kit (Seikagaku Cor- poration, Tokyo Japan) |
| Assay Data | None |
| Validation Techniques used | BDG G test |
| Up Regulation Down Regulation | Negative-Prognostic |
| Sequence Data | None |
| External Link | None |
